Investment Rating - The investment rating for the company is "Buy" with an expected relative increase of over 15% in the next 6-12 months compared to the relevant market index [40]. Core Insights - The company, Aide Technology (920180.BJ), primarily engages in the research, production, and sales of orthopedic medical devices, focusing on spinal, trauma, and sports medicine products, as well as wound healing products [6][8]. - The company has a strong market position in the orthopedic field, particularly in the spinal segment, with a market share of 1.29% in 2023, ranking sixth among domestic companies in the spinal implant market [33]. - Revenue projections for 2023-2025 are 262 million, 275 million, and 302 million yuan respectively, with year-over-year growth rates of -8.22%, 4.87%, and 9.74% [8][3]. - The company has launched new products in the hip and knee joint categories, expanding its product line and aiming for steady revenue growth [34]. Summary by Sections Basic Financial Status - The company achieved revenues of 262.1 million yuan in 2023, with a net profit of 63.6 million yuan, reflecting a year-over-year decline of 31.85% [3][8]. - The revenue for 2024 is projected to be 274.9 million yuan, with a slight recovery in net profit to 67.1 million yuan, indicating a growth of 5.60% [3][8]. Industry Situation - The orthopedic medical device industry is experiencing growth, driven by an aging population and increasing healthcare spending, with the market size expected to grow from 193 billion yuan in 2016 to 246 billion yuan by 2024 [16][17]. - The spinal implant market specifically is projected to recover in 2024, with a market size of 72 billion yuan, following a decline due to national procurement policies [18]. Company Highlights - Aide Technology has developed a comprehensive product matrix covering all areas of orthopedics, with 132 product registrations and a focus on the lower-tier medical market [33][34]. - The company has established a nationwide sales network, collaborating with over 3,000 hospitals across 31 provinces and municipalities [33]. Fundraising Project Investment - The company plans to invest in three main projects through its IPO: an orthopedic consumables expansion project, a research and development center, and a marketing network enhancement project [35][36]. Comparison with Peers - Compared to peer companies like Weigao Orthopedics and Dabo Medical, Aide Technology's revenue and gross margin are below the average, with a projected revenue of 2.75 billion yuan for 2024 [37][38].

Industry Investment Rating - The report maintains an investment rating of "Outperform" for the orthopedic consumables sector [2]. Core Insights - The orthopedic consumables sector experienced significant performance improvement in H1 2025, with a positive trend in overseas expansion and accelerated corporate layouts [3][5]. - The overall revenue of the A-share orthopedic consumables sector increased by 16% year-on-year in H1 2025, with net profit attributable to shareholders rising by 70% and non-recurring net profit increasing by 75% [5][11]. - The gross profit margin for the sector was 66% in H1 2025, reflecting a year-on-year increase of 1.95 percentage points, attributed to ongoing cost control and optimization [5][11]. - The report highlights a favorable trend in overseas business, which is expected to become a significant growth driver for companies in the sector [5][35]. Summary by Sections 1. Orthopedic Consumables H1 2025 Report Analysis - The orthopedic consumables sector saw a revenue increase of 16.24% in H1 2025, with a gross profit margin of 66.07% [9][11]. - The second quarter of 2025 showed a revenue growth of 23% year-on-year, with net profit growth of 84% [11]. 2. Segment Analysis - The joint business segment benefited from the implementation of centralized procurement policies, leading to a sustained increase in both volume and price for leading companies [22]. - The spinal segment is experiencing stable execution of centralized procurement, with significant room for domestic companies to increase market share [29]. 3. Related Company Summaries - **Dabo Medical**: Achieved a revenue of 12.1 billion yuan in H1 2025, a year-on-year increase of 25.55%, with a net profit of 2.44 billion yuan, up 76.69% [41]. - **Weigao Orthopedics**: Reported a revenue of 7.41 billion yuan in H1 2025, a slight decrease of 1.28%, but net profit increased by 52.43% [57]. - **Aikang Medical**: Generated a revenue of 6.94 billion yuan in H1 2025, reflecting a growth of 5.65% year-on-year [47]. - **Chunli Medical**: Recorded a revenue of 4.88 billion yuan in H1 2025, up 28.27% year-on-year [52]. - **Sanyou Medical**: Achieved a revenue of 2.50 billion yuan in H1 2025, a year-on-year increase of 17.77% [61].